Last 18,100 KRW
Change Today -50.00 / -0.28%
Volume 598.5K
000230 On Other Exchanges
Symbol
Exchange
Korea SE
As of 10:22 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

il dong pharmaceutical co lt (000230) Snapshot

Open
18,300
Previous Close
18,150
Day High
18,700
Day Low
17,800
52 Week High
09/17/14 - 18,800
52 Week Low
10/8/13 - 9,900
Market Cap
453.7B
Average Volume 10 Days
636.2K
EPS TTM
268.00
Shares Outstanding
25.1M
EX-Date
12/27/13
P/E TM
67.5x
Dividend
160.00
Dividend Yield
0.88%
Current Stock Chart for IL DONG PHARMACEUTICAL CO LT (000230)

Related News

No related news articles were found.

il dong pharmaceutical co lt (000230) Related Businessweek News

No Related Businessweek News Found

il dong pharmaceutical co lt (000230) Details

Ildong Pharmaceutical Co., Ltd. provides various pharmaceutical products in South Korea. The company offers active lactic acid bacteria and anti-diarrheal agents, antibiotics, antifungals and antivirals, anti-histamine drugs, antineoplastic agents, NSAIDs and analgesics, topical preparations, vitamins, and mineral and nutrients; and drugs for blood circulation, cardiovascular system, central nervous system, dental treatment, endocrine and metabolic systems, gastrointestinal system, respiratory system, and urogenital system. It also provides raw material drugs, such as synthesis, probiotics, and biometabolites; health foods and foods; cosmetics; medical devices; and other products. The company also exports its products to Japan, Vietnam, Azerbaijan, Cambodia, Dominican Republic, Guatemala, Indonesia, Malaysia, Mexico, Myanmar, Pakistan, the Philippines, Singapore, Vietnam, Yemen, etc. The company was formerly known as Keukdong Pharmaceuticals Co., Ltd. and changed its name to Ildong Pharmaceutical Co., Ltd. in May 1942. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Founded in 1941

il dong pharmaceutical co lt (000230) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

il dong pharmaceutical co lt (000230) Key Developments

ILDong Pharmaceutical Co. Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014

ILDong Pharmaceutical Co. Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 . Venue: Kempinski Hotel Suzhou, Suzhou, China.

ILDong Pharmaceutical Co. Ltd. - Shareholder/Analyst Call

To cover company's performance and key management status

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan

CoLucid Pharmaceuticals, Inc. and ILDong Pharmaceutical Co. Ltd. have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia. Under the terms of the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to ILDONG for development and commercialization of Lasmiditan in the territory. ILDONG will be responsible for the costs and activities related to development and regulatory approvals in the territory and will also participate in key registration trials as part of the global development plan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000230:KS 18,100.00 KRW -50.00

000230 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000230.
View Industry Companies
 

Industry Analysis

000230

Industry Average

Valuation 000230 Industry Range
Price/Earnings 21.1x
Price/Sales 1.0x
Price/Book 1.2x
Price/Cash Flow 18.9x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IL DONG PHARMACEUTICAL CO LT, please visit www.ildong.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.